NCT02539719 (Clinical Trial/ SC-003)

Study Title
Study of SC-003 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer (NCT02539719)

Trial Description
This is a Phase 1a/1b study of SC-003 in patients with platinum-resistant/refractory ovarian cancer. SC-003 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody linked to a potent chemotherapy.

This trial is sponsored by Stemcentrx®.

Study Data

  • Condition:
    • Ovarian Cancer
  • Interventions:
    • Drugs used in this trial
      • SC-003
  • Phase: I
  • Estimated Enrollment: 108
  • Start: August 2015
  • Estimated Completion: February 2017
  • Last updated: April 2016
  • Last verified: April 2016

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: August 3, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.